Company intelligence / Profile preview
Xi'an Xintong Pharmaceutical Research Co., Ltd.
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
Overview
Xi'an Xintong Pharmaceutical Research is a leading Chinese pharmaceutical company with over 200 CFDA-approved drugs. It develops innovative, generic, and traditional Chinese medicines. The company has several commercialized products and an active pipeline targeting infectious diseases, CNS disorders, and women’s health. Notable clinical results include approval of Pradefovir Mesylate for hepatitis B in China and late-stage development of Fosphenytoin Sodium for epilepsy/status epilepticus.
- Therapeutic areas
- Women's HealthNeurologyInfectious Diseases
- Modalities
- Small molecule drugsHerbal medicine (Traditional Chinese Medicine)Chemical drugs
- Industry
- Pharma
Drug pipeline
10 assets9 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Xi'an Xintong Pharmaceutical Research Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xi'an Xintong Pharmaceutical Research Co., Ltd..